September 24, 2016 10:12 PM ET

Biotechnology

Company Overview of Moderna Therapeutics, Inc.

Company Overview

Moderna Therapeutics, Inc. develops messenger RNA therapeutics. The company provides in vivo drug modality that produces human proteins or antibodies inside patient cells. It also develops various patent applications with various claims ranging from novel nucleotide chemistries to specific drug compositions. The company focuses on disease areas, such as inherited genetic disorders, hemophilic and blood factors, and oncology. Moderna Therapeutics, Inc. has strategic option agreements with AstraZeneca and Alexion Pharmaceuticals, Inc.; and strategic collaborations with Karolinska Institutet, Institut Pasteur, Karolinska University Hospital, and Merck. The company was incorporated in 2009 and i...

200 Tech Square

Cambridge, MA 02139

United States

Founded in 2009

Phone:

617-714-6500

Fax:

617-583-1998

Key Executives for Moderna Therapeutics, Inc.

Founding Chief Executive Officer and Director
Age: 43
Co-Founder, Chairman and Member of Technology Advisory Board
Age: 53
Chief Financial Officer
Age: 42
President of Research and Development
Age: 62
Compensation as of Fiscal Year 2016.

Moderna Therapeutics, Inc. Key Developments

Moderna Therapeutics to Build Fully Integrated GMP mRNA Clinical Manufacturing Facility in Norwood, Massachusetts

Moderna Therapeutics announced that it has signed a long-term lease (15 years plus renewal options) to build a Good Manufacturing Practices (GMP) clinical manufacturing facility in Norwood, Massachusetts. Moderna is committed to developing a broad array of medicines leveraging its leading mRNA platform, and to delivering on the promise of mRNA science for patients as quickly as possible. To support and manage this anticipated breadth of clinical studies, Moderna’s 200,000 square foot Norwood facility will enable the manufacture, quality, control and supply of clinical grade mRNA therapies and vaccines for Good Laboratory Practices (GLP) toxicology studies as well as Phase 1 and Phase 2 clinical studies. At the site, Moderna will carry out all manufacturing activities "from raw material production to active pharmaceutical ingredients (APIs), formulation, filling and finish. Moderna will begin initial build-out of the new facility in October 2016. The company plans to open the facility by early 2018.

Moderna Therapeutics Appoints Melissa J. Moore as Chief Scientific Officer of its mRNA Research Platform, Effective October 3, 2016

Moderna Therapeutics announced that Melissa J. Moore, Ph.D., has been appointed Chief Scientific Officer (CSO) of Moderna’s mRNA research platform. Responsible for leading all mRNA biology research at Moderna, Dr. Moore will play a critical leadership role as the company enters a new growth phase, and will help guide Moderna towards its vision of delivering on the promise of mRNA science for patients. Dr. Moore will assume her new role at Moderna as of October 3, 2016. Currently a member of Moderna’s Scientific Advisory Board, Dr. Moore joins the company from the University of Massachusetts Medical School (UMMS), where she is currently Professor of Biochemistry & Molecular Pharmacology, Eleanor Eustis Farrington Chair in Cancer Research and Investigator at the Howard Hughes Medical Institute (HHMI). In addition, Dr. Moore was a founding Co-Director of the RNA Therapeutics Institute (RTI) at UMMS. Upon joining Moderna, Dr. Moore will resign from HHMI, but retain her academic affiliation with UMMS as a part-time faculty member.

Moderna Therapeutics, Inc. Presents at The 23rd Annual NewsMakers in the Biotech Industry Conference, Sep-09-2016

Moderna Therapeutics, Inc. Presents at The 23rd Annual NewsMakers in the Biotech Industry Conference, Sep-09-2016. Venue: Millennium Broadway Hotel & Conference Center, New York, New York, United States. Presentation Date(s): Sep-09-2016.

Similar Private Companies By Industry

Company Name Region
20n Labs, Inc. United States
23andMe, Inc. United States
2C Tech Corporation, Inc. United States
3-V Biosciences, Inc. United States
3D Bio Holdings LLC United States

Recent Private Companies Transactions

Type
Date
Target
Private Placement
August 10, 2016
--
Private Placement
July 6, 2016
--
Private Placement
October 22, 2015
Valera LLC
 

The information and data displayed in this profile are created and managed by Capital IQ, a Standard & Poor's company. Bloomberg.com does not create or control the content. For inquiries, please contact Capital IQ directly by clicking here.

Stock Quotes

Market data is delayed at least 15 minutes.

Company Lookup

Most Searched Private Companies

Company Name Geographic Region
Lawyers Committee for Civil Rights Under Law United States
NYC2012, Inc. United States
Bertelsmann AG Europe
Rush University United States
Bloomberg L.P. United States

Sponsored Financial Commentaries

Sponsored Links

Request Profile Update

Only a company representative may request an update for the company profile. Documentation will be required.

To contact Moderna Therapeutics, Inc., please visit www.modernatx.com. Company data is provided by Capital IQ. Please use this form to report any data issues.

Please enter your information in the following field(s):
Update Needed*

All data changes require verification from public sources. Please include the correct value or values and a source where we can verify.

Your requested update has been submitted

Our data partners will research the update request and update the information on this page if necessary. Research and follow-up could take several weeks. If you have questions, you can contact them at bwwebmaster@businessweek.com.